Delving into the Latest Updates on GSK-3901961 with Synapse

Overview

Basic Info

Drug Type

TCR-T Cell therapy

Synonyms

GSK 3901961, GSK-3901961

Target

HLA class I antigen

Action

modulators

Mechanism

HLA class I antigen modulators

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication-

Inactive Indication

Advanced Malignant Solid NeoplasmLAGE-1a Positive Solid Tumorsmetastatic non-small cell lung cancer+ [3]

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

Adaptimmune Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NYESO1 and LAGE1a, and Co-expressing CD8α (GSK3901961) in Participants With NYESO1 and/or LAGE1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma / Myxoid/Round Cell Liposarcoma; or NYESO1 and/or LAGE1a Positive Previously Treated Metastatic Non-Small Cell Lung Cancer

The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A*02:01, HLA-A*02:05 and/or HLA A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or Cancer testis antigen 2 (LAGE 1a) positive previously treated metastatic Non-Small Cell Lung Cancer (NSCLC) and previously treated, advanced (metastatic or unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma SS/MRCLS.

Start Date09 Mar 2021

Sponsor / Collaborator

Adaptimmune Ltd.

NCT04526509

/ TerminatedPhase 1

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

Start Date21 Dec 2020

Sponsor / Collaborator

Adaptimmune Ltd.

100 Clinical Results associated with GSK-3901961

Login to view more data

100 Translational Medicine associated with GSK-3901961

Login to view more data

100 Patents (Medical) associated with GSK-3901961

Login to view more data

100 Deals associated with GSK-3901961

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
metastatic non-small cell lung cancer	Phase 1	United States	Adaptimmune Ltd.	09 Mar 2021
metastatic non-small cell lung cancer	Phase 1	Australia	Adaptimmune Ltd.	09 Mar 2021
metastatic non-small cell lung cancer	Phase 1	Canada	Adaptimmune Ltd.	09 Mar 2021
metastatic non-small cell lung cancer	Phase 1	Germany	Adaptimmune Ltd.	09 Mar 2021
metastatic non-small cell lung cancer	Phase 1	Netherlands	Adaptimmune Ltd.	09 Mar 2021
metastatic non-small cell lung cancer	Phase 1	Sweden	Adaptimmune Ltd.	09 Mar 2021
Myxoid Liposarcoma	Phase 1	United States	Adaptimmune Ltd.	09 Mar 2021
Myxoid Liposarcoma	Phase 1	Australia	Adaptimmune Ltd.	09 Mar 2021
Myxoid Liposarcoma	Phase 1	Canada	Adaptimmune Ltd.	09 Mar 2021
Myxoid Liposarcoma	Phase 1	Germany	Adaptimmune Ltd.	09 Mar 2021